Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: A clinical report
2003 (English)In: European Journal of Cancer, ISSN 0959-8049, Vol. 39, no 1, 70-77 p.Article in journal (Refereed) Published
Fifty-seven patients with MAGE-3-positive measurable metastatic cancer, most of them with melanoma, were vaccinated with escalating doses of a recombinant MAGE-3 protein combined with a fixed dose of the immunological adjuvant SBAS-2, which contained MPL and QS21. The immunisation schedule included 4 intramuscular (i.m.) injections at 3-week intervals. Patients whose tumour stabilised or regressed after 4 vaccinations received 2 additional vaccinations at 6-week intervals. The vaccine was generally well tolerated. Among the 33 melanoma patients who were evaluable for tumour response, we observed 2 partial responses, 2 mixed responses and 1 stabilisation. Time to progression in these 5 patients varied from 4 to 29 months. In addition, a partial response lasting 10 months was observed in 1 of the 3 metastatic bladder cancer patients included. None of the tumour responses described above involved visceral metastases. Immunological responses to the vaccine will be reported separately. ⌐ 2002 Elsevier Science Ltd. All rights reserved.
Place, publisher, year, edition, pages
2003. Vol. 39, no 1, 70-77 p.
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:liu:diva-25097DOI: 10.1016/S0959-8049(02)00479-3Local ID: 9529OAI: oai:DiVA.org:liu-25097DiVA: diva2:245423